Abstract Many properties of polypropylene mesh that are causative in producing the complications that our patients are experiencing were published in the literature prior to the marketing of most currently used mesh configurations and mesh kits. These factors were not sufficiently taken into account prior to the sale of these products for use in patients. This report indicates when this information was available to both mesh kit manufacturers and the Food and Drug Administration.
There has been a lack of dissemination of information regarding many of the characteristics of polypropylene mesh especially the many factors which are implicated in the complications that our patients experience postoperatively. The first polypropylene mesh kit cleared by the US Food and Drug Administration (FDA) for implantation was that used in the transvaginal tape (TVT®) procedure for the treatment of stress incontinence. This clearance was granted in 1998. Previously in 1996, a woven polyester mesh kit was cleared and further meshes and mesh kits meshes were granted clearance in the ensuing years. All FDA information regarding clearance for marketing dates is available at http://www.fda. gov/MedicalDevices/default.htm. I will concentrate here on those factors known to influence the behavior of mesh in vivo until 2003, when many more new mesh kits were cleared by the FDA. Heat effects and degradation will be summarized.
Relevant information has accumulated since the 1950s and was available in the medical literature for many years before FDA clearance of various meshes and mesh kits as outlined below (PP: polypropylene; SEM: scanning electron microscopy; FBGC: foreign body giant cells):
1953 Any implanted device must not be physically modified by tissue fluids, be chemically inert, not incite an inflammatory or foreign body cell response, be non-carcinogenic, not produce allergic reactions, stand up to mechanical stress, be fabricated in form required at low cost and be capable of sterilization [1] . 1962 PP monofilament suture had high tensile strength, good flexibility and resistance to fatigue along with good knot retention along with being inert with excellent chemical resistance [2] . 1967 One hundred bacteria were enough to cause infection of a multfilament suture and monofilament suture withstood infection [3] . 1967 Monofilament suture is better than multifilament suture in wound infections [4] . 1973 Granulation formation related to friction between tissue and implant [5] . 1977 Immobile bacteria propagate inside multifilament suture and this plays a role in the spread of infection [6] . 1979 Bacteria are protected in interstices of material [7] . 1981 Bacterial adherence to multifilament suture 5-8 times greater than monofilament suture as documented with SEM [8] . 1980 Pore size is important for tissue incorporation [9] . 1983 Bacteria are protected in interstices from phagocytosis since leukocytes cannot readily enter the small pores of multifilament suture which supports infection and may result in sustained and prolonged infection [10, 11] . 1983 Multifilament sutures harbor bacteria at 70 days after implantation as shown with SEM [12] . 1984 Heat exposed PP releases biologically active degradation products affecting normal metabolic events [13] . 1986 Degradation of PP suture known as seen with SEM [14] . 1987 Immediately upon insertion of a mesh there is a race to the mesh surface between bacteria and host defense cells [15] .
1991 Bacteria adhere more to hydrophobic surfaces and produce a biofilm which further protects them from phagocytosis and antibiotics [16] . 1993 Multifilament mesh with a histiocytic reaction and unstable fixation which promotes infection [17] . 1993 Bacteria migrate along synthetic polymeric fibers [18] .
ProteGen® Sling Mesh Kit FDA Clearance Letter Dated November 15, 1996 1996 Multifilament Surgipro® mesh has more FBGCs than monofilament PP mesh [19] . 1997 High and low responders indentified by tumor necrosis factor measurements [20] .
TVT® FDA Clearance Letter Dated January 28, 1998
1998 Bacteria adhere to biomaterials using a biofilm [21] . 1998 PP mesh shrinks 30-50% after 4 weeks [22] . 1999 A multifilament mesh must be removed with infection [23] . 1999 Surface roughness promotes wicking of bacteria [24] . 1999 Ten bacterial colony forming units are enough to infect 15% of multifilament meshes [25] . 2001 Greater pore size leads to more deposition of mature collagen with increased tensile strength and vascularity. Pores <12 microns prevent vascularization [27] . 2001 The abdominal wall stiffens after mesh insertion [28] . An abundance of information was available for both the FDA and mesh manufacturers prior to the FDA clearance of most meshes. Many publications detailed degradation mechanisms including heat exposure during manufacture and bacterial colonization of the polypropylene used in pelvic repair meshes. 
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